摘要
目的研究马来酸噻吗洛尔联合普萘洛尔对浅表型婴幼儿血管瘤(IHs)患儿的作用。方法将纳入的IHs患儿75例随机分为3组:第1干预组(单纯口服普萘洛尔1.5 mg·kg-1)26例、第2干预组(单纯局部外用0.5%马来酸噻吗洛尔滴眼液)25例和第3干预组(0.5%马来酸噻吗洛尔滴眼液+普萘洛尔1.0 mg·kg-1)24例。比较几组临床有效率、治疗后7 d血浆基质金属蛋白酶-9(MMP-9)和肾素水平。结果第1干预组、第2干预组和第3干预组的临床有效率分别为61.54%,60.00%和91.67%;这3组的MMP-9水平分别为(997.44±78.76),(1036.13±145.94)和(899.54±78.32)pg·mL-1;这3组的肾素水平分别为(265.25±21.45),(246.27±22.43)和(187.59±18.11) pg·mL-1。上述指标:第3干预组与第1干预组、第2干预组比较,差异均有统计学意义(均P<0.05)。结论马来酸噻吗洛尔联合普萘洛尔治疗浅表型IHs见效快、疗程短且效果显著。
Objective To investigate the effect of timolol maleate combined with propranolol in the treatment of superficial infantile hemangiomas(IHs).Methods A total of 75 cases of IHs were selected, and randomly divided into three groups:Intervetion-1 group(26 cases) was given the 1.5 mg·kg-1 oral propranolol;intervetion-2 group(25 cases) was given the topical tinolol maleate 0.5% solution, and intervetion-3 group(24 cases) was given topical tinolol maleate 0.5% solution combined with 1.0 mg·kg-1 oral propranolol.Plasma matrix metalloproteinase-9(MMP-9) and renin levels were detected and compared at 7 d after treatment.Results The clinical efficacy rate in intervetion-1 group,intervetion-2 group and intervetion-3 group were 61.54%,60.00% and 91.67%;the MMP-9 level in the three groups were(997.44±78.76),(1036.13±145.94)and(899.54±78.32)pg·mL-1;the renin level in the three groups were(265.25±21.45),(246.27±22.43)and(187.59±18.11) pg·mL-1.Compared between intervetion-3 group and intervetion-1 group,intervetion-2 group,the difference of the factors were sinificant(all P<0.05).Conclusion Collaboration of timolol maleate and propranolol in the treatment of superficial IHs presents rapid efficacy and short treatment course.
作者
张娅琴
雷智贤
黄婷
冯乃超
ZHANG Ya-qin;LEI Zhi-xian;HUANG Ting;FENG Nai-chao(Division of Neonatology,Hainan Women and Children Medical Center,Haikou 57000,Hainan Province,China;Intensive Care Unit,Hainan Women and Children Medical Center,Haikou 57000,Hainan Province,China;Department of Respiratory,Hainan Women and Children Medical Center,Haikou 57000,Hainan Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第4期362-365,共4页
The Chinese Journal of Clinical Pharmacology
基金
海南省自然科学基金资助项目(20163076)。
